Pharmaceutical
- Pharmaceutical intermediates
- Heterocyclic Compound
- OLED material intermediate
- Diphenylamine intermediates
- Nutritional Supplements
- Pharmaceutical raw materials
Human APIs Powder
- Respiratory Drugs Raw Material
- Antiviral Antibacterial
- Antipyretic Analgesics
- Antihistamine Drugs
- Antineoplastic
- Urinary System Drugs
- Endocrine System
- Other
Medicine Excipients
Veterinary raw materials
Phone: 86-29-89601602
E-mail: sales21@interlgroup.com
Add: Fengcheng 2nd Road, Weiyang District, Xi'an, Shaanxi, China
Cabozantinib Malate CAS 1140909-48-3 Raw Materials Powder
Product Overview:
Cabozantinib Malate Powder is a small molecule C-Met modulator. Cabozantinib malate acts as a potent multi-target VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50s of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively.Cabozantinib Malate CAS 1140909-48-3 showed dose-dependent inhibition of tumor growth and tumor regression associated with disruption of the tumor vascular system and extensive tumor apoptosis.Cabozantinib Malate Raw Materials primarily targets MET and VEGFR2 tyrosine kinases associated with prostate cancer growth and proliferation, inhibiting tumor metastasis and vascular The main target of Cabozantinib Malate Raw Materials is MET and VEGFR2 tyrosine kinases, which are associated with prostate cancer growth and proliferation, to inhibit tumor metastasis and angiogenesis.
Cabozantinib Malate CAS 1140909-48-3 Raw Materials Powder Attributes
CAS: 1140909-48-3
MF: C32H30FN3O10
MW: 635.6
EINECS: 691-711-0
Specification: 99% min Cabozantinib Malate
Sample: Cabozantinib Malate Powder
Brand: Henrikang
Appearance: White Powder
Storage: Cool Dry Place
Shelf Life: 2 Years
Test Method: HPLC
Cabozantinib Malate CAS 1140909-48-3 Raw Materials Powder Details
Cabozantinib Malate Powder Usage and Synthesis.
Cabozantinib Malate Powder is a small molecule C-Met modulator. Cabozantinib malate acts as a potent multi-target VEGFR2, Met, FLT3, Tie2, Kit and Ret inhibitor with IC50s of 0.035, 1.8, 14.4, 14.3 and 4.6 nM for VEGFR2, Met, FLT3, Tie2 and Kit, respectively.
Cabozantinib Malate CAS 1140909-48-3 showed dose-dependent inhibition of tumor growth and tumor regression associated with disruption of the tumor vascular system and extensive tumor apoptosis.
Cabozantinib Malate Raw Materials primarily targets MET and VEGFR2 tyrosine kinases associated with prostate cancer growth and proliferation, inhibiting tumor metastasis and vascular The main target of Cabozantinib Malate Raw Materials is MET and VEGFR2 tyrosine kinases, which are associated with prostate cancer growth and proliferation, to inhibit tumor metastasis and angiogenesis.
Application/Function of Cabozantinib Malate Powder.
Cabozantinib Malate was developed by Exelixis Biopharmaceuticals, Inc. It targets MET and VEGFR2 tyrosine kinases, which are associated with the growth and spread of prostate cancer, to inhibit tumor metastasis and angiogenesis.
Pharmacological effect of Cabozantinib Malate Powder
CabozantinibS-MALATE, formerly known as XL184, was developed by Exelixis Biopharmaceuticals, Inc. It targets MET and VEGFR2 tyrosine kinases, which are associated with the growth and spread of prostate cancer, to inhibit tumor metastasis and angiogenesis.
Cabozantinib malate, the malate salt of Cabozantinib, is a potent VEGFR2 inhibitor with an IC50 of 0.035nM and also inhibits c-Met, Ret, Kit, Flt-1/3/4, Tie2 and AXL with IC50s of 1.3nM, 4nM, 4.6nM, 12nM/11.3nM/6nM, respectively. 14.3nM and 7nM.
